{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:19:56Z","timestamp":1773958796682,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11906-007-0066-7","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T07:19:08Z","timestamp":1191395948000},"page":"353-359","source":"Crossref","is-referenced-by-count":37,"title":["Resistant hypertension and aldosteronism"],"prefix":"10.1007","volume":"9","author":[{"given":"Eduardo","family":"Pimenta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,4]]},"reference":[{"key":"66_CR1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"key":"66_CR2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","volume":"290","author":"I. Hajjar","year":"2003","unstructured":"Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000. JAMA 2003, 290:199\u2013206.","journal-title":"JAMA"},{"key":"66_CR3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"W.C. Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393\u2013404.","journal-title":"J Clin Hypertens"},{"key":"66_CR4","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"C.J. Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease\u2014the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805\u20132816.","journal-title":"JAMA"},{"key":"66_CR5","first-page":"3","volume":"45","author":"J.W. Conn","year":"1955","unstructured":"Conn JW: Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:3\u201317.","journal-title":"J Lab Clin Med"},{"key":"66_CR6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","volume":"20","author":"R.D. Gordon","year":"1993","unstructured":"Gordon RD, Ziesak MD, Tunny TJ, et al.: Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296\u2013298.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"66_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"R.D. Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"66_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L. Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonz\u00e1lez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161\u2013165.","journal-title":"Hypertension"},{"key":"66_CR9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"D.A. Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"key":"66_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"B.J. Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:669\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"66_CR11","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"I.K. Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226.","journal-title":"J Hypertens"},{"key":"66_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","volume":"17","author":"B. Strauch","year":"2003","unstructured":"Strauch B, Zelinka T, Hampf M, et al.: Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349\u2013352.","journal-title":"J Hum Hypertens"},{"key":"66_CR13","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802\u2013H1810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"66_CR14","first-page":"893","volume":"120","author":"C.G. Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"66_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1291\/hypres.27.303","volume":"27","author":"A. Sato","year":"2004","unstructured":"Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004, 27:303\u2013310.","journal-title":"Hypertens Res"},{"key":"66_CR16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"G.P. Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039\u20131045.","journal-title":"Hypertension"},{"key":"66_CR17","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","volume":"69","author":"C.S. Fox","year":"2006","unstructured":"Fox CS, Larson MG, Hwang S-J, et al.: Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064\u20132069.","journal-title":"Kidney Int"},{"key":"66_CR18","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"M.K. Nishizaka","year":"2004","unstructured":"Nishizaka MK, Zaman MA, Green SA, et al.: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857\u20132861.","journal-title":"Circulation"},{"key":"66_CR19","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P. Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldostronism. J Am Coll Cardiol 2005, 45:1243\u20131248.","journal-title":"J Am Coll Cardiol"},{"key":"66_CR20","first-page":"257","volume":"62","author":"J.W. Conn","year":"1968","unstructured":"Conn JW: The evolution of primary aldosteronism. Harvey Lect 1968, 62:257\u2013291.","journal-title":"Harvey Lect"},{"key":"66_CR21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"M.K. Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"66_CR22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","volume":"18","author":"M.K. Nishizaka","year":"2005","unstructured":"Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al.: Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805\u2013812.","journal-title":"Am J Hypertens"},{"key":"66_CR23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneph0151","volume":"2","author":"C. Mattsson","year":"2006","unstructured":"Mattsson C, Young WF Jr: Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006, 2:198\u2013208.","journal-title":"Nat Clin Pract Nephrol"},{"key":"66_CR24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archsurg.141.5.497","volume":"141","author":"F.E. Nwariaku","year":"2006","unstructured":"Nwariaku FE, Miller BS, Auchus R, et al.: Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006, 141:497\u2013503.","journal-title":"Arch Surg"},{"key":"66_CR25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"A.M. Sawka","year":"2001","unstructured":"Sawka AM, Young WF, Thompson GB, et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258\u2013261.","journal-title":"Ann Intern Med"},{"key":"66_CR26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10557-005-6127-8","volume":"19","author":"B.M. Goessens","year":"2005","unstructured":"Goessens BM, Visseren FL, Olijhoek JK, et al.: Multidisciplinary vascular screening program modestly improves treatment of vascular risk factors. Cardiovasc Drugs Ther 2005, 19:429\u2013435.","journal-title":"Cardiovasc Drugs Ther"},{"key":"66_CR27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjhyper.2004.11.021","volume":"18","author":"J.P. Garg","year":"2005","unstructured":"Garg JP, Elliott WJ, Folker A, et al.: Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18:619\u2013626.","journal-title":"Am J Hypertens"},{"key":"66_CR28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjhyper.2004.11.002","volume":"18","author":"H.O. Ventura","year":"2005","unstructured":"Ventura HO, Taler SJ, Strobeck JE: Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens 2005, 18:26\u201343S.","journal-title":"Am J Hypertens"},{"key":"66_CR29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J. Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333\u2013339.","journal-title":"Am J Hypertens"},{"key":"66_CR30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","volume":"18","author":"A. Mahmud","year":"2005","unstructured":"Mahmud A, Mahgoub M, Hall M, Feely J: Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens 2005, 18:1631\u20131635.","journal-title":"Am J Hypertens"},{"key":"66_CR31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"D.A. Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891\u2013894.","journal-title":"J Hypertens"},{"key":"66_CR32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N. Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839\u2013845.","journal-title":"Hypertension"},{"key":"66_CR33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"J.M. Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"66_CR34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","volume":"46","author":"C. Saha","year":"2005","unstructured":"Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481\u2013487.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-007-0066-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0066-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:19Z","timestamp":1559434459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-007-0066-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s11906-007-0066-7","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}